Document Detail


Active surveillance: the Canadian experience with an "inclusive approach".
MedLine Citation:
PMID:  23271779     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Active surveillance has evolved to become a standard of care for favorable-risk prostate cancer. This is a summary of the rationale, method, and results of active surveillance beginning in 1995 with the first prospective trial of this approach. This was a prospective, single-arm cohort study. Patients were managed with an initial expectant approach. Definitive intervention was offered to those patients with a prostate-specific antigen (PSA) doubling time of less than 3 years, Gleason score progression (to 4+3 or greater), or unequivocal clinical progression. Survival analysis and Cox proportional hazard model were applied to the data. Since November 1995, 450 patients have been managed with active surveillance. The cohort included men under 70 with favorable-risk disease and men of age more than 70 with favorable- or intermediate-risk cancer (Gleason score 3+4 or PSA 10-15). Median follow-up is 6.8 years (range 1-16 years). Overall survival is 78.6%. Ten-year prostate cancer actuarial survival is 97.2%. Five of 450 patients (1.1%) have died of prostate cancer. Thirty percent of patients have been reclassified as higher-risk patients and offered definitive therapy. The commonest indication for treatment was a PSA doubling time less than 3 years (48%) or Gleason upgrading (26%). Of 117 patients treated radically, the PSA failure rate was 50%. This represents 13% of the total cohort. Most PSA failures occurred early; at 2 years, 44% of the treated patients had PSA failure. The hazard ratio for non-prostate cancer mortality to prostate cancer mortality was 18.6 at 10 years. In conclusion, we observed a very low rate of prostate cancer mortality in an intermediate time frame. Among the one-third of patients who were reclassified as higher risk and retreated, PSA failure was relatively common. However, other-cause mortality accounted for almost all of the deaths. Further studies are warranted to improve the identification of patients who harbor more aggressive disease in spite of favorable clinical parameters at diagnosis [reproduced from Klotz (1) with permission from Wolters Kluwer Health].
Authors:
Laurence Klotz
Related Documents :
22901109 - Advanced imaging applications for locally advanced cervical cancer.
23471749 - The incidence of palb2 c.3113g>a in women with a strong family history of breast and ov...
22982839 - Assessing an intervention to improve clinical trial perceptions among predominately afr...
23673479 - Dna repair genes polymorphism and lung cancer risk with the emphasis to sex differences.
23695019 - Prognostic value of pten loss in men with conservatively managed localised prostate can...
23663559 - Outcome of 12 month surveillance colonoscopy in high risk patients in the nhs bowel can...
15380579 - Potential survival advantage with early androgen deprivation for biochemical failure af...
21144559 - Pathologic findings following false-positive screening tests for ovarian cancer in the ...
3019199 - Is bone marrow examination in small-cell lung cancer really necessary?
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of the National Cancer Institute. Monographs     Volume:  2012     ISSN:  1745-6614     ISO Abbreviation:  J. Natl. Cancer Inst. Monographs     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-28     Completed Date:  2013-06-21     Revised Date:  2013-09-03    
Medline Journal Info:
Nlm Unique ID:  9011255     Medline TA:  J Natl Cancer Inst Monogr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  234-41     Citation Subset:  IM    
Affiliation:
Sunnybrook Health Sciences Centre, Division of Urology, University of Toronto, 2075 Bayview Ave, Toronto, Ontario. Laurence.klotz@sunnybrook.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Canada
Cohort Studies
Disease Progression
Humans
Male
Neoplasm Grading
Prospective Studies
Prostate-Specific Antigen / blood
Prostatic Neoplasms / diagnosis,  mortality*,  therapy*
Risk
Survival
Survival Analysis
Watchful Waiting*
Chemical
Reg. No./Substance:
EC 3.4.21.77/Prostate-Specific Antigen
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Results from the Scandinavian Prostate Cancer Group Trial Number 4: a randomized controlled trial of...
Next Document:  Quality of life in men undergoing active surveillance for localized prostate cancer.